Berger Montague PC Investigating Claims on Behalf of MoonLake Immunotherapeutics (NASDAQ: MLTX) Investors After Class Action Filing

PHILADELPHIA, Oct. 20, 2025 (GLOBE NEWSWIRE) -- National plaintiffs’ law firm Berger Montague PC announces a class action lawsuit against MoonLake Immunotherapeutics (NASDAQ: MLTX) (“MoonLake” or the “Company”) on behalf of investors who purchased MoonLake shares during the period of March 10, 2024 through September 29, 2025 (the “Class Period”).

Investor Deadline: Investors who purchased MoonLake securities during the Class Period may, no later than December 15, 2025, seek to be appointed as a lead plaintiff representative of the class. To learn your rights, CLICK HERE.

MoonLake, based in Zug, Switzerland, is a clinical-stage biotech firm focused on advancing next-generation immunotherapies.

According to the complaint, the Company repeatedly promoted its only drug candidate, sonelokimab (SLK), as a breakthrough treatment due to its Nanobody structure. The lawsuit alleges that the Company failed to disclose that SLK targets the same molecules as BIMZELX, an FDA-approved monoclonal antibody, and thus was not clinically superior to BIMZELX.

According to the suit, on September 28, 2025, the Company disclosed Phase 3 trial results for SLK revealing that the drug failed to meet efficacy benchmarks. Analysts reportedly described the outcome as “disastrous,” and MoonLake’s stock price declined by $55.75 per share – nearly 90% – in a single trading session.

If you are a MoonLake investor and would like to learn more about this action, CLICK HERE or please contact Berger Montague: Andrew Abramowitz at aabramowitz@bergermontague.com or (215) 875-3015, or Caitlin Adorni at cadorni@bergermontague.com or (267)764-4865.

About Berger Montague
Berger Montague, with offices in Philadelphia, Minneapolis, Delaware, Washington, D.C., San Diego, San Francisco, Chicago, Malvern, PA, and Toronto has been a pioneer in securities class action litigation since its founding in 1970. Berger Montague has represented individual and institutional investors for over five decades and serves as lead counsel in courts throughout the United States.

For more information or to discuss your rights, please contact:
Andrew Abramowitz
Senior Counsel
Berger Montague
(215) 875-3015
aabramowitz@bergermontague.com

Caitlin Adorni
Director of Portfolio & Institutional Client Monitoring Services
Berger Montague
(267) 764-4865
cadorni@bergermontague.com

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.